XOMA (NASDAQ:XOMA) Lowered to "Sell" Rating by StockNews.com

XOMA (NASDAQ:XOMA - Get Free Report) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Friday.

Separately, HC Wainwright restated a "buy" rating and set a $123.00 price objective on shares of XOMA in a report on Friday, December 13th.

XOMA Price Performance

XOMA traded down $0.98 during trading on Friday, hitting $26.30. The company's stock had a trading volume of 11,277 shares, compared to its average volume of 22,988. The firm's 50 day moving average price is $29.82 and its two-hundred day moving average price is $27.80. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $309.89 million, a price-to-earnings ratio of -7.56 and a beta of 0.88. XOMA has a 12 month low of $18.24 and a 12 month high of $35.00.

Insiders Place Their Bets

In other news, CEO Owen Hughes sold 21,881 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares of the company's stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.20% of the company's stock.

Hedge Funds Weigh In On XOMA

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 795 shares in the last quarter. Rhumbline Advisers lifted its position in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock worth $230,000 after purchasing an additional 1,334 shares during the period. Barclays PLC grew its stake in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after buying an additional 8,447 shares in the last quarter. Ellsworth Advisors LLC bought a new position in XOMA in the 3rd quarter valued at about $516,000. Finally, Bank of New York Mellon Corp raised its position in shares of XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock valued at $1,484,000 after buying an additional 1,968 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.